Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.63 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 2/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18567421 | 1.00 | BACE1 (0.63) | BACE1TRPV3CTSDGRM3APP | |
| SCHEMBL13467022 | 0.90 | BACE1 (0.49) | BACE1TRPV3 | |
| SCHEMBL18567433 | 0.90 | BACE1 (0.49) | BACE1TRPV3 | |
| SCHEMBL15693547 | 0.89 | BACE1 (0.48) | BACE1 | |
| SCHEMBL13466988 | 0.82 | BACE1 (0.41) | BACE1 | |
| SCHEMBL18567422 | 0.77 | BACE1 (0.51) | BACE1TRPV3GRM3APPMCHR1 | |
| SCHEMBL18567441 | 0.75 | BACE1 (0.40) | BACE1 | |
| SCHEMBL13467261 | 0.74 | BACE1 (0.39) | BACE1CTSD | |
| SCHEMBL13467021 | 0.70 | BACE1 (0.64) | BACE1 | |
| SCHEMBL13466955 | 0.67 | BACE1 (0.62) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697210-B1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9499502-B2 | 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20140128382-A1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO- AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME LLC | 2014-05-08 | — | — | US | disclosed |
| WO-2012139425-A1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS,COMPOSITIONS,AND THEIR USE | SCHERING CORPORATION (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128382-A1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO- AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, PSEN1 | BACE1 1/4885TRPV3 3704/4885CTSD 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.